Types of Bestrophinopathies

Bestrophinopathies are a group of inherited eye disorders that affect the retina, particularly the macula—the central part responsible for sharp, detailed vision. These conditions arise due to mutations in the BEST1 gene, which encodes the bestrophin-1 protein. Bestrophin-1 is essential for normal fluid transport and electrical signaling in the retinal pigment epithelium (RPE), a layer of cells that nourishes and supports light-sensing photoreceptors. When bestrophin-1 is faulty, waste materials accumulate beneath the retina, leading to characteristic lesions, vision disturbances, and, over time, progressive vision loss. Although individual forms vary in severity and age of onset, all Bestrophinopathies share a genetic basis and disruptions in RPE function.

Bestrophinopathies are a group of inherited eye disorders caused by mutations in the BEST1 gene, which encodes the Bestrophin-1 protein in the retinal pigment epithelium (RPE). These mutations disrupt fluid and ion transport between the RPE and photoreceptors, leading to build-up of lipofuscin and “egg-yolk” lesions in the macula. Over time, this damage impairs central vision, causing blurred or distorted sight, color changes, and difficulty reading EyeWiki.

---

Types of Bestrophinopathies

Bestrophinopathies encompass several related disorders, each distinguished by genetic inheritance patterns, lesion appearance, and clinical course:

1. Best Vitelliform Macular Dystrophy (BVMD): The classic “egg-yolk” lesion appears in childhood or adolescence, often causing mild to moderate central vision loss.

2. Adult-Onset Vitelliform Macular Dystrophy (AVMD): Similar lesions emerge in middle age, usually progressing more slowly and causing milder symptoms than BVMD.

3. Autosomal Recessive Bestrophinopathy (ARB): A rarer form caused by two mutated BEST1 copies, leading to widespread RPE changes, fluid buildup under the macula, and earlier, more severe vision impairment.

4. Angle-Closure Glaucoma with Bestrophinopathy Features: Some patients develop narrow drainage angles and increased eye pressure alongside typical Best disease changes.

5. Other Atypical Variants: Including multifocal lesions, extramacular involvement, and mixed phenotypes that combine features of BVMD, ARB, and AVMD.

---

Causes of Bestrophinopathies

1. BEST1 Gene Mutation (Missense): The most common cause involves a single-letter change in DNA that alters bestrophin-1’s shape, disrupting its channel function in the RPE.

2. BEST1 Gene Mutation (Nonsense): A mutation introduces a premature stop command, producing an incomplete, nonfunctional protein and causing severe RPE dysfunction.

3. BEST1 Gene Deletion: Loss of an entire piece of the gene prevents any bestrophin-1 production, often leading to early-onset, aggressive forms.

4. Compound Heterozygosity: Two different BEST1 mutations—one from each parent—combine to impair protein function, typical in autosomal recessive Bestrophinopathy.

5. Dominant Negative Effect: A mutated protein interferes with normal bestrophin-1 produced from the healthy gene copy, exacerbating RPE malfunction.

6. Age-Related Accumulation of Lipofuscin: In Best disease, impaired fluid transport leads to buildup of lipofuscin pigment under the retina, which damages the RPE over time.

7. Oxidative Stress in the RPE: Faulty bestrophin-1 channels can’t regulate ion balance, making RPE cells more vulnerable to damaging free radicals.

8. Disrupted Calcium Signaling: Bestrophin-1 normally responds to calcium signals; mutations hinder this, altering RPE cell health and fluid regulation.

9. Inflammatory Microenvironment: Chronic RPE damage may trigger low-grade inflammation, further injuring photoreceptors and supporting cells.

10. Environmental Oxidants: Exposure to bright sunlight or smoking can increase oxidative damage in an already vulnerable RPE.

11. Systemic Metabolic Disorders: Conditions like diabetes can worsen RPE stress, contributing to earlier symptom onset in genetically predisposed individuals.

12. Age-Related Cell Senescence: As patients age, RPE repair mechanisms slow, magnifying the effects of faulty bestrophin-1 channels.

13. Other Genetic Modifiers: Variations in additional genes can influence disease severity and progression among individuals with the same BEST1 mutation.

14. Autoimmune Reactions: In rare cases, antibodies against RPE components may compound the primary genetic defect.

15. Epigenetic Changes: Altered gene expression patterns—triggered by environment or aging—can reduce BEST1 activity even without direct DNA mutations.

---

Symptoms of Bestrophinopathies

1. Blurry Central Vision: Patients notice difficulty reading fine print or recognizing faces due to macular involvement.

2. Metamorphopsia (Distorted Vision): Straight lines may appear wavy or bent, reflecting irregularities in the retinal surface.

3. Scotomas (Blind Spots): Small areas of vision loss develop around the central field, making tasks like driving challenging.

4. Reduced Contrast Sensitivity: Trouble distinguishing subtle shades, especially in low light or against busy backgrounds.

5. Photophobia (Light Sensitivity): Bright lights cause discomfort, as damaged RPE cannot regulate retinal illumination effectively.

6. Color Vision Deficiency: Difficulty perceiving colors accurately, particularly distinguishing blues and yellows.

7. Delayed Dark Adaptation: Slow adjustment when moving from bright to dim environments, due to impaired photoreceptor support.

8. Reading Fatigue: Eyes tire quickly when reading or focusing on detailed tasks, reflecting RPE stress.

9. Paracentral Vision Loss: In some variants, vision loss spreads beyond the fovea, causing difficulty in peripheral fine tasks.

10. Glare Sensitivity: Halos or glare around lights at night, complicating activities like nighttime driving.

---

Diagnostic Tests for Bestrophinopathies

Physical Examination

1. Visual Acuity Test: Measures clarity of central vision using standardized letters. Detects the degree of vision loss in each eye.

2. Amsler Grid: A simple grid pattern helps patients self-report distortion or missing areas, indicating macular irregularities.

Manual Tests

3. Ophthalmoscopic Examination: The ophthalmologist uses a special light and magnifying lens to view the retina’s surface, identifying “egg-yolk” lesions.

4. Slit-Lamp Biomicroscopy: A focused light beam and microscope enable detailed examination of the anterior and posterior eye segments, revealing subtle RPE changes.

Laboratory and Pathological Tests

5. Genetic Testing (BEST1 Sequencing): Blood or saliva sample is analyzed to identify specific BEST1 mutations, confirming diagnosis at the DNA level.

6. Blood Lipofuscin Marker Study: Although not routine, researchers may measure systemic markers of lipofuscin accumulation to gauge disease activity.

Electrodiagnostic Tests

7. Electrooculography (EOG): Records standing potential across the RPE; Bestrophinopathies classically show a reduced “light peak” response.

8. Electroretinography (ERG): Measures electrical responses of photoreceptors and inner retinal cells; helps distinguish Best disease from other maculopathies.

Imaging Tests

9. Optical Coherence Tomography (OCT): Provides cross-sectional images of retinal layers, revealing subretinal fluid, vitelliform material, and RPE atrophy.

10. Fundus Autofluorescence (FAF): Detects natural fluorescence from lipofuscin, mapping areas of RPE damage and monitoring lesion progression.

11. Fluorescein Angiography (FA): Dye injected into a vein highlights blood flow in retinal vessels, showing leaks or blocked areas under the macula.

12. Indocyanine Green Angiography (ICGA): Similar to FA but uses a different dye to visualize deeper choroidal vessels, assessing choroidal involvement.

13. Multicolor Imaging: Uses multiple wavelengths to enhance contrast of retinal features, improving visualization of early vitelliform lesions.

14. Adaptive Optics Scanning Laser Ophthalmoscopy (AO-SLO): High-resolution imaging of photoreceptors, useful in research settings to assess cellular integrity.

15. Fundus Photography: Standard color photographs document lesion appearance and track changes over time.

16. Near-Infrared Reflectance (NIR): Highlights RPE melanin changes, complementing FAF in detecting early pathology.

17. B-Scan Ultrasonography: Sound waves produce a two-dimensional image, useful when media opacities (e.g., cataract) obscure direct viewing.

18. Blue-Light Autofluorescence: Another variant of FAF that accentuates certain lipofuscin fluorophores, aiding early diagnosis.

19. OCT Angiography (OCT-A): Noninvasively maps retinal and choroidal microvasculature, detecting subtle vascular changes without dye injection.

20. Spectral-Domain OCT (SD-OCT): An advanced OCT providing higher resolution and faster acquisition, ideal for detailed mapping of RPE and photoreceptor layers.

Non-Pharmacological Treatments

(Subdivided into Exercise Therapies, Mind-Body Approaches, and Educational Self-Management)

Exercise Therapies

1. Oculomotor Saccade Training
   Description: Guided exercises that train rapid eye movements to shift focus between targets.
   Purpose: Improve scanning efficiency across the visual field.
   Mechanism: Repeated saccades strengthen neural pathways, enhancing visual search and reading speed.

2. Pursuit Movement Drills
   Description: Tracking a slowly moving object for several minutes.
   Purpose: Enhance smooth pursuit eye control.
   Mechanism: Reinforces coordination between cortex and ocular motor nuclei to stabilize images.

3. Eccentric Viewing Practice
   Description: Learning to fixate using a healthier retinal area outside the damaged fovea.
   Purpose: Maximize use of residual vision for central tasks.
   Mechanism: Neuroplastic adaptation shifts fixation locus, reducing reliance on the central scotoma.

4. Fixation Stability Exercises
   Description: Holding gaze on a small dot for increasing durations.
   Purpose: Improve the steadiness of fixation on objects.
   Mechanism: Strengthens fine control of ocular muscles to minimize micro-saccades.

5. Visual Search Strategy Training
   Description: Systematic scanning patterns to locate objects in cluttered scenes.
   Purpose: Reduce search time in daily tasks like finding items on shelves.
   Mechanism: Builds efficient cortical mapping for object recognition in peripheral vision.

6. Contrast Sensitivity Drills
   Description: Differentiating grating patterns of varying contrast.
   Purpose: Enhance the ability to discern low-contrast details under dim lighting.
   Mechanism: Stimulates retinal processing cells to amplify weak signal detection.

7. Eye–Hand Coordination Tasks
   Description: Eye-guided target-tapping exercises on touchscreens.
   Purpose: Improve integration of visual input with motor response.
   Mechanism: Tightens visuomotor feedback loops between parietal cortex and motor cortex.

Mind-Body Approaches

1. Mindfulness Meditation
   Description: Daily 10–20 minute sessions focusing on breath and awareness.
   Purpose: Reduce stress and improve emotional coping with vision loss.
   Mechanism: Lowers cortisol levels, indirectly preserving retinal health by reducing systemic oxidative stress.

2. Progressive Muscle Relaxation
   Description: Sequentially tensing and relaxing muscle groups.
   Purpose: Alleviate tension headaches and eye strain.
   Mechanism: Promotes parasympathetic activation, improving ocular blood flow.

3. Guided Imagery
   Description: Visualization of calm scenes to distract from visual impairment.
   Purpose: Enhance quality of life by reducing anxiety and depressive symptoms.
   Mechanism: Activates limbic pathways to modulate stress and pain perception.

4. Yoga-Based Breathing Exercises
   Description: Pranayama techniques like alternate-nostril breathing.
   Purpose: Improve overall circulation, including ocular perfusion.
   Mechanism: Balances autonomic tone, optimizing blood flow to the retina.

5. Biofeedback Training
   Description: Using devices to monitor heart rate or skin conductance during relaxation.
   Purpose: Teach patients to consciously control stress responses.
   Mechanism: Enhances self-regulation of vascular tone, potentially benefiting choroidal circulation.

6. Cognitive-Behavioral Therapy (CBT)
   Description: Structured sessions with a psychologist to reframe negative thoughts.
   Purpose: Address depression and adjustment disorder related to vision loss.
   Mechanism: Modifies maladaptive cognitive patterns, improving adherence to rehabilitation.

Educational Self-Management

1. Genetic Counseling Sessions
   Description: Scheduled meetings with a genetic counselor.
   Purpose: Inform patients and families about inheritance, risks, and family planning.
   Mechanism: Empowers decision-making, reducing uncertainty and emotional distress.

2. Amsler Grid Self-Monitoring
   Description: Daily check of the central grid pattern at home.
   Purpose: Early detection of new distortion or scotomas.
   Mechanism: Monitors progression to prompt timely medical intervention NCBI.

3. Smartphone Vision-Tracking Apps
   Description: Apps that record daily visual acuity and distortion.
   Purpose: Provide clinicians with trend data between visits.
   Mechanism: Digital logs allow for fine-tuned adjustments in management plans.

4. UV and Blue-Light Protection Education
   Description: Information on selecting proper eyewear and filters.
   Purpose: Minimize photo-oxidative damage to the RPE.
   Mechanism: Physical blocking of high-energy wavelengths reduces free-radical formation.

5. Home Lighting Optimization
   Description: Guidance on lamp placement and bulb selection.
   Purpose: Enhance contrast and reduce glare for reading and tasks.
   Mechanism: Maximizes retinal signal-to-noise ratio by controlling ambient illumination.

6. Nutritional Counseling
   Description: Diet plans rich in antioxidants and omega-3s.
   Purpose: Support general retinal health and reduce oxidative stress.
   Mechanism: Ingested nutrients scavenge free radicals and stabilize photoreceptor membranes.

7. Peer Support Group Participation
   Description: Regular meetings with others affected by inherited retinal diseases.
   Purpose: Share coping strategies and reduce isolation.
   Mechanism: Social engagement improves mental health and treatment adherence.

---

Key Pharmacological Agents

These primarily address complications, as no cure exists for Bestrophinopathies

1. Ranibizumab (Lucentis)

   • Class: Anti-VEGF monoclonal antibody fragment

   • Dosage: 0.5 mg intravitreal injection monthly

   • Timing: Typically every 4 weeks, then treat-and-extend

   • Side Effects: Conjunctival hemorrhage, eye pain, increased IOP, endophthalmitis Medscape.

2. Bevacizumab (Avastin)

   • Class: Anti-VEGF full-length antibody (off-label)

   • Dosage: 1.25 mg intravitreal injection monthly

   • Timing: Every 4 weeks, per response

   • Side Effects: Similar to ranibizumab; systemic VEGF suppression risk.

3. Aflibercept (Eylea)

   • Class: VEGF-Trap fusion protein

   • Dosage: 2 mg intravitreal injection every 8 weeks after three monthly doses

   • Timing: Every 2 months maintenance

   • Side Effects: Floaters, eye irritation, rare thromboembolic events.

4. Pegaptanib (Macugen)

   • Class: RNA aptamer targeting VEGF-165

   • Dosage: 0.3 mg intravitreal injection every 6 weeks

   • Timing: Historically every 6 weeks; largely replaced by newer agents.

5. Verteporfin (Visudyne)

   • Class: Photosensitizer for PDT

   • Dosage: 6 mg/m² IV infusion over 10 min, followed by 689 nm laser activation

   • Timing: Single session; repeat as needed every 3 months

   • Side Effects: Back pain, injection site redness, photosensitivity for 48 hours.

6. Triamcinolone Acetonide

   • Class: Intravitreal corticosteroid

   • Dosage: 4 mg intravitreal injection

   • Timing: Every 3–6 months based on edema recurrence

   • Side Effects: Steroid-induced glaucoma, cataract progression.

7. Dexamethasone Implant (Ozurdex)

   • Class: Sustained-release corticosteroid implant

   • Dosage: One 0.7 mg implant intravitreal

   • Timing: Up to every 6 months

   • Side Effects: Elevated IOP, cataract NCBI.

8. Fluocinolone Acetonide Implant (Iluvien)

   • Class: Long-term intravitreal corticosteroid implant

   • Dosage: One 0.19 mg implant (releases 0.2 μg/day)

   • Timing: Up to 36 months

   • Side Effects: Significant cataract risk, ocular hypertension.

9. Oral Acetazolamide

   • Class: Carbonic anhydrase inhibitor

   • Dosage: 500 mg daily in divided doses

   • Timing: Short courses to reduce subretinal fluid

   • Side Effects: Paresthesia, kidney stones, metabolic acidosis.

10. Bortezomib (Investigational Proteasome Inhibitor)

    • Class: Proteasome inhibitor under early study

    • Dosage & Timing: Trial-dependent dosing

    • Side Effects: Peripheral neuropathy, GI upset; not yet approved for Bestrophinopathies.

---

Dietary Molecular Supplements

(Dosage, Function, Mechanism)

1. Lutein (10 mg/day)

   • Function: Macular pigment enhancer

   • Mechanism: Filters blue light and scavenges free radicals in the retina.

2. Zeaxanthin (2 mg/day)

   • Function: Complementary macular pigment

   • Mechanism: Works with lutein to protect photoreceptors from oxidative damage.

3. Omega-3 Fatty Acids (DHA + EPA, 1000 mg/day)

   • Function: Anti-inflammatory support

   • Mechanism: Modulates eicosanoid pathways to reduce retinal inflammation.

4. Vitamin C (500 mg twice daily)

   • Function: Antioxidant defense

   • Mechanism: Neutralizes reactive oxygen species in ocular tissues.

5. Vitamin E (400 IU/day)

   • Function: Lipid membrane stabilizer

   • Mechanism: Prevents peroxidation of photoreceptor outer segment membranes.

6. Zinc (80 mg/day)

   • Function: Cofactor for antioxidant enzymes

   • Mechanism: Enhances activity of superoxide dismutase in the RPE.

7. Copper (2 mg/day)

   • Function: Balance zinc supplementation

   • Mechanism: Prevents copper deficiency anemia from high-dose zinc.

8. Resveratrol (150 mg/day)

   • Function: Mitochondrial support

   • Mechanism: Activates SIRT1 to improve RPE mitochondrial function.

9. Anthocyanins (Bilberry extract, 160 mg/day)

   • Function: Vascular health

   • Mechanism: Promotes microcirculation in choroidal vessels.

10. Curcumin (500 mg twice daily)

    • Function: Anti-inflammatory and antioxidant

    • Mechanism: Inhibits NF-κB and reduces cytokine-mediated damage in the RPE.

---

Regenerative & Stem Cell-Based Therapies

(Dosage, Function, Mechanism—All investigational)

1. AAV2-hBEST1 Gene Therapy

   • Dosage: ~1×10¹¹ vector genomes via subretinal injection

   • Function: Restore BEST1 expression in RPE cells

   • Mechanism: Delivers functional BEST1 gene to correct ion channel defects.

2. CRISPR/Cas9 Gene Editing

   • Dosage: Trial-dependent; localized subretinal delivery

   • Function: Precise correction of pathogenic BEST1 mutations

   • Mechanism: Uses guided nuclease to repair DNA in RPE cells.

3. iPSC-Derived RPE Cell Transplantation

   • Dosage: ~100,000 RPE cells via subretinal graft

   • Function: Replace damaged RPE layer

   • Mechanism: Provides healthy RPE to resume normal photoreceptor support.

4. Mesenchymal Stem Cell (MSC) Injection

   • Dosage: 1×10⁶ cells intravitreal

   • Function: Neuroprotective and anti-inflammatory support

   • Mechanism: MSCs secrete trophic factors that protect photoreceptors.

5. Photoreceptor Precursor Cell Transplantation

   • Dosage: Trial-specific cell counts via subretinal delivery

   • Function: Replenish lost photoreceptors

   • Mechanism: Differentiates into rods/cones, integrating into the retina.

6. Dual AAV Vector Best1 Replacement

   • Dosage: Two complementary AAV vectors totaling ~2×10¹¹ vg

   • Function: Overcome packaging limits for full-length BEST1 gene

   • Mechanism: Reassembles functional gene in situ for RPE expression.

---

Surgical & Office Procedures

1. Subretinal Injection (Gene & Cell Therapy)

   • Procedure: Surgical delivery of vector/cells beneath the retina under local anesthesia.

   • Benefits: Directly targets RPE layer; minimized systemic exposure.

2. Photodynamic Therapy (PDT)

   • Procedure: Intravenous verteporfin followed by low-energy laser activation on CNV.

   • Benefits: Selectively closes abnormal vessels while sparing surrounding tissue.

3. Intravitreal Injection (Drugs & MSCs)

   • Procedure: Office-based needle injection into the vitreous cavity.

   • Benefits: Minimally invasive; allows repeated delivery of drugs or cells.

4. Argus II Retinal Prosthesis

   • Procedure: Implantation of microelectrode array on the retinal surface linked to an external camera.

   • Benefits: Provides rudimentary form vision in advanced cases.

5. Macular Translocation Surgery

   • Procedure: Rotates the macula to healthier RPE under the fovea.

   • Benefits: Temporarily improves central vision by relocating photoreceptors.

---

Prevention Strategies

1. Genetic Counseling – Early identification of carriers and family planning.

2. Family Screening – Eye exams for relatives to detect early disease.

3. UV/Blue-Light Protection – Wear wraparound sunglasses and blue-light filters.

4. Healthy Diet – Emphasize antioxidant-rich foods to support retinal health.

5. Smoking Cessation – Eliminates a major source of oxidative stress.

6. Regular Eye Exams – At least annual dilated fundus evaluations.

7. Blood Pressure Control – Avoids hypertensive choroidopathy.

8. Blood Sugar Management – Minimizes diabetic retinopathy risk.

9. Head Protection – Wear helmets/glasses to prevent ocular trauma.

10. Monitor Screen Time – Reduce prolonged glare and near work strain.

---

When to See a Doctor

• New or Worsening Distortion: Sudden changes in the Amsler grid.

• Rapid Vision Loss: Drop of more than two lines on the eye chart.

• Floaters or Flashes: Possible retinal tears or detachment.

• Eye Pain or Redness: Signs of infection or inflammation.

• Headaches with Visual Changes: Could indicate increased ocular pressure.

• Medication Side Effects: Any eye discomfort after injections.

• Pre-Surgical Consult: Before any regenerative therapy.

• Pregnancy Planning: Genetic counseling prior to conception.

• Traveling to High Altitudes: Risk of choroidal expansion complications.

• Vision Rehabilitation Referral: When adaptive strategies are needed.

---

“Do’s” and “Don’ts”

Do’s

1. Use low-vision aids (magnifiers, telescopic lenses).

2. Maintain a stable, well-lit environment.

3. Perform daily Amsler grid tests.

4. Adhere to injection schedules.

5. Keep blood pressure and sugar under control.

6. Eat a balanced, antioxidant-rich diet.

7. Join support groups for coping strategies.

8. Wear UV/blue-light protective eyewear.

9. Communicate any changes promptly to your doctor.

10. Practice prescribed visual exercises.

Don’ts

1. Avoid bright glare without protection.

2. Don’t skip scheduled eye exams.

3. Refrain from smoking or vaping.

4. Don’t self-prescribe supplements without guidance.

5. Avoid excessive screen time without breaks.

6. Don’t ignore sudden visual changes.

7. Refrain from heavy lifting immediately after injections.

8. Don’t miss genetic counseling appointments.

9. Avoid unproven “miracle” treatments.

10. Don’t underestimate mental health—seek help if needed.

---

Frequently Asked Questions

1. What is the inheritance pattern of Bestrophinopathies?
   They are most often autosomal dominant but can be autosomal recessive in some forms.

2. Can I pass this condition to my children?
   If you carry a dominant mutation, each child has a 50% chance of inheriting it.

3. Is there a cure?
   No cure exists yet; management focuses on preserving vision and treating complications.

4. Will my vision go completely?
   Total blindness is rare, but central vision can decline significantly over decades.

5. Are there clinical trials I can join?
   Yes, several gene and stem cell therapy trials are ongoing worldwide.

6. How often should I have an eye exam?
   At least once a year, or more frequently if CNV or fluid develops.

7. Can diet slow progression?
   A diet rich in antioxidants and omega-3s may help but cannot prevent genetic damage.

8. Are injections painful?
   They cause mild discomfort and last only a few seconds under local anesthesia.

9. What risks do injections carry?
   Rarely, infection (endophthalmitis), bleeding, or increased eye pressure can occur.

10. Is genetic testing necessary?
    It confirms diagnosis, guides family planning, and may determine trial eligibility.

11. Can I drive with Best disease?
    Many can continue driving with peripheral vision; regulations vary by region.

12. What vision aids help most?
    Electronic magnifiers and head-mounted displays offer superior magnification and contrast.

13. Is low-vision rehab covered by insurance?
    Coverage varies; refer to your plan’s durable medical equipment and therapy benefits.

14. Can exercise make my eyes worse?
    General aerobic exercise is safe and may improve ocular blood flow; avoid high-impact sports without protection.

15. Will future therapies restore normal vision?
    Gene and cell therapies hold promise; early trials show improved RPE function and slowed progression.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 14, 2025.